# Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

> **NCT04493099** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Alvocidib Hydrochloride
- **DRUG:** Decitabine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04493099
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10
- **Primary completion:** 2020-10-12
- **Final completion:** 2020-10-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The original sponsor was acquired by a new company and has elected to end funding for all Investigator Sponsored Trials (ISTs)
- **Last updated:** 2020-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04493099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04493099, "Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04493099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*